American Society of Clinical Oncology

SHERPA: White

People

  1. Scheinberg
    Scheinberg
  2. Zelenetz
    Zelenetz
  3. Panageas
    Panageas
  4. Noy
    Noy
  5. Berman
    Berman
  6. Palomba
    Palomba
  7. Park
    Park
  8. Sadelain
    Sadelain
  9. Wang
    Wang

Groups

  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. Hematologic Malignancies, Division of (11)
  4. Adult Leukemia (8)
  5. GSK Faculty (7)
  6. Hematologic Malignancies Research (7)
  7. Lymphoma (6)
  8. Molecular Pharmacology and Chemistry Program Faculty (6)
  9. Sloan Kettering Institute Faculty (6)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (5)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "Nicole Lamanna"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. Hematologic Malignancies, Division of (11)
  4. Adult Leukemia (8)
  5. GSK Faculty (7)
  6. Hematologic Malignancies Research (7)

More Groups

People
  1. Nicole Lamanna (11)
  2. Joseph Jurcic (7)
  3. Peter Maslak (7)
  4. Andrew Zelenetz (5)
  5. David Scheinberg (5)
  6. Mark Weiss (5)

More People

Years
  1. 2014 (2)
  2. 2013 (1)
  3. 2012 (2)
  4. 2011 (1)
  5. 2009 (1)
  6. 2006 (1)

More Years

Publications
  1. Journal of Clinical Oncology (11)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results
    Meeting Abstract

    Ghia, P.; O'Brien, S. M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Barrientos, J. C.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL
    Meeting Abstract

    Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Meeting Abstract

    O'Brien, S. M.; Lamanna, N.; Kipps, T. J.; Flinn, I.; Zelenetz, A. D.; Burger, J. A.; Holes, L.; Johnson, D. M.; Gu, J.; Dansey, R. D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Safety and efficacy of dose escalated liposomal amphotericin B in adult leukemia patients with refractory invasive fungal infections: A single institution report
    Meeting Abstract

    Mathew, S.; Harnicar, S.; Halton, E.; Berman, E.; Brentjens, R. J.; Heaney, M. L.; Jurcic, J. G.; Lamanna, N.; Maslak, P. G.; Rosenblat, T. L.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A new paradigm in CLL: Minimizing toxicity by using the minimum effective dose (MED) of lenalidomide for older patients with CLL
    Meeting Abstract

    Lamanna, N.; Heaney, M. L.; Maslak, P. G.; Jurcic, J. G.; Rosenblat, T. L.; Noy, A.; Palomba, M. L.; Weiss, M. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells
    Meeting Abstract

    Brentjens, R. J.; Riviere, I.; Park, J.; Davilla, M.; Wang, X.; Yeh, R.; Lamanna, N.; Frattini, M. G.; Sadelain, M.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
    Journal Article

    Lamanna, N.; Jurcic, J. G.; Noy, A.; Maslak, P.; Gencarelli, A. N.; Panageas, K. S.; Heaney, M. L.; Brentjens, R. J.; Golde, D. W.; Scheinberg, D. A.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J. G.; Heaney, M.; Brentjens, R.; Zelenetz, A. D.; Horgan, D.; Gencarelli, A.; Panageas, K. S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL
    Meeting Abstract

    Weiss, M. A.; Heffner, L.; Lamanna, N.; Kalaycio, M.; Schiller, G.; Coutre, S.; Maslak, P.; Jurcic, J.; Panageas, K.; Scheinberg, D. A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia
    Meeting Abstract

    Weiss, M. A.; Lamanna, N.; Kalaycio, M.; Jurcic, J.; Maslak, P.; Gencarelli, A.; Scheinberg, D.; Horgan, D.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save